Livagen 20 mg

About Livagen

Livagen is a lab-made peptide of four amino acids: lysine, glutamic acid, aspartic acid and alanine (Lys-Glu-Asp-Ala, or KEDA).¹² Khavinson's group made it by directed chemical synthesis, based on amino acid analysis of liver polypeptide preparations.¹ Most studies come from the St. Petersburg Institute of Bioregulation and Gerontology and a collaborating genetics group at Tbilisi State University in Georgia.¹³¹³ This page lists Livagen for sale as a 20 mg research vial, with stock for each shipping origin in the selector above.

PubMed holds 19 records for Livagen, and ClinicalTrials.gov lists no trial.¹⁴⁵ Its "human" data come from blood cells taken from elderly donors and treated in the lab.³⁴ Before you buy Livagen for a study, read What is Livagen? for the full findings, including results that conflict.

Research highlights

• Rat liver cells (2001): Livagen raised protein synthesis in hepatocytes from rats aged 1 to 24 months, most in cells from old rats.¹ Epitalon did not change it.¹
• Donor blood cells (2002, 2004): Livagen loosened tightly packed chromatin and reactivated ribosomal genes in lymphocytes from old people, including donors aged 75 to 88.³⁴
• A conflicting result (2023): a later study of lymphocytes from 75- to 88-year-olds found that the bioregulators tested, Livagen among them, did not loosen structural chromatin near chromosome centers, unlike the earlier reports.¹³
• Metal exposure, donor cells (2007): in lymphocytes from donors aged 80 to 91 exposed to cobalt chloride, Livagen reduced the number of chromosome changes.¹⁵
• Enzymes, test tube (2003): Livagen blocked enkephalin-degrading enzymes in human serum with an IC50 of 20 micromolar, against 500 for Epitalon.⁷
• Rats given Livagen by mouth (2005): after two weeks, digestive enzyme activity fell in young rats and rose in old rats.¹⁶
• Liver disease models (2020 review): the developer group reports high efficiency for Livagen and a liver polypeptide complex (Ventvil) in animal models of liver fibrosis and hepatitis and in cell studies.²

Regulatory status

Livagen is not FDA approved: an October 2026 search of FDA's approval data found no product with it as an active ingredient.¹¹ It is not on FDA's May 14, 2026 list of bulk substances nominated for compounding under section 503A.¹⁷ Health Canada's August 1, 2025 advisory lists Livagen among unauthorized injectable peptide drugs seized from and sold by a Canadian seller.¹² The advisory says injectable peptides are regulated as prescription drugs in Canada and that selling unauthorized drugs is illegal there, and it warns that unauthorized injectable drugs may cause infection and allergic reactions.¹² WADA's 2026 list does not name Livagen, but its class S0 bans at all times any substance not covered by the list's other sections that has no government approval for human therapeutic use.¹⁸ The 2027 list, in force January 1, 2027, adds peptides to the S0 examples.¹⁹

Handling and storage

The supplier says to mix Livagen with bacteriostatic water, keep the mixed vial in the refrigerator and use it within 30 days.⁶ That is supplier guidance, not published stability data.⁶ GenScript warns that repeated freeze-thaw cycles degrade peptides.⁹ It suggests splitting a stock into aliquots sized for each experiment, which also limits air exposure.⁹ Livagen contains Asp, a residue GenScript links to an especially short life in solution.⁹ The reconstitution guide lists the lab steps, and the reconstitution calculator gives the concentration for a chosen diluent volume.